The Role of Factor IX in Tissue Thromboplastin Induced Coagulation

Summary

Tissue thromboplastin apoprotein was partially purified from human brain. The apoprotein was recombined with mixed phospholipids to yield active thromboplastin. The recombined thromboplastin induced proteolytic activation of isolated human factor IX in the presence of factor VII and Ca²⁺. The clotting times of various deficient plasmas were determined as a function of apoprotein concentration, keeping the phospholipid concentration constant. The clotting times of a factor XII-deficient plasma were the same as those of a factor XII/factor IX-deficient plasma, except at very low apoprotein concentrations. However, under those conditions the difference in clotting times was independent of the presence of anti-factor VII serum. Similar observations were made for factor XI-deficient plasma in comparison with factor XI/factor IX-deficient plasma. These results indicate that activation of factor IX by factor VII/tissue thromboplastin does not significantly contribute to plasma coagulation.

Keywords

Plasma coagulation - Tissue thromboplastin - Factor IX - Extrinsic pathway - Intrinsic pathway - Alternative pathways

• References

• 1 Zur M, Nemerson Y. Tissue factor pathways of blood coagulation. In: Bloom AL, Thomas DP. (eds.) Haemostasis and thrombosis . Churchill Livingstone, Edinburgh, London, Melbourne; New York: 124-139 1981
• 2 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
• 3 Zur M, Nemerson Y. Kinetics of factor IX activation via the extrinsic pathway. Dependence of Km on tissue factor. J Biol Chem 1980; 255: 5703-5707
• 4 Jesty J, Silverberg SA. Kinetics of the tissue factor-dependent activation of coagulation factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-12345
• 5 Østerud B, Rapaport SI. Activation of ¹²⁵I-factor IX and ¹²⁵I-factor X: effect of tissue factor and factor VII, factor Xa and thrombin. Scand J Haematol 1980; 24: 213-226
• 6 Van den Besselaar AMHP, Ram IE, Bertina RM. Involvement of human factor IX in tissue thromboplastin induced coagulation. Thromb Haemostas 1981; 46: 34 (Abstr.).
• 7 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
• 8 Wang C, Smith RL. Lowry determination of protein in the presence of Triton X-100. Anal Biochem 1975; 63: 414-417
• 9 Folch L, Lees M, Sloane StanleyGH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957; 226: 497-509
• 10 Bottcher CJF, Van Gent CM, Pries C. A rapid and sensitive submicro phosphorus determination. Anal Chim Acta 1961; 24: 203-204
• 11 Holloway PW. A simple procedure for removal of Triton X-100 from protein samples. Anal Biochem 1973; 53: 304-308
• 12 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
• 13 Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. Biochem J 1980; 185: 647-658
• 14 Bertina RM, Veltkamp JJ. The abnormal factor IX of hemophilia B⁺ variants. Thromb Haemostas 1978; 40: 335-349
• 15 Hvatum M, Prydz H. Studies on tissue thromboplastin – its splitting into two separable parts. Thrombos Diathes Haemorrh 1969; 21: 217-222
• 16 Bjorklid E, Storm E, Prydz H. The protein component of human brain thromboplastin. Biochem Biophys Res Commun 1973; 55: 969-976
• 17 Carson SD, Konigsberg WH. Coagulation factor III from human brain and placenta. Am J Hum Genet 1980; 32: A37
• 18 Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-1538
• 19 Walsh PN. The effect of dilution of plasma on coagulation: the significance of the dilution-activation phenomenon for the study of platelet coagulant activities. Br J Haematol 1972; 22: 219-236
• 20 Didisheim P, Mibashan RS. Activation of Hageman factor (factor XII) by long-chain saturated fatty acids. Thrombos Diathes Haemorrh 1963; 9: 346-353
• 21 Tans G, Griffin JH. Properties of sulfatides in factor XII-dependent contact activation. Blood 1982; 59: 69-75
• 22 Østerud B, Kasper CK, Lavine KK, Prodanos C, Rapaport SI. Purification and properties of an abnormal blood coagulation factor IX (factor IX_Bm). Kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor. Thromb Haemostas 1981; 45: 55-59
• 23 Seligsohn U, Østerud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems. Roles of activated factor IX, kallikrein, and activated factor XII. J din Invest 1979; 64: 1056-1065
• 24 Østerud B, Rapaport SI, Schiffman S, Chong MMY. Formation of intrinsic factor-X activator activity, with special reference to the role of thrombin. Br J Haematol 1971; 21: 643-660
• 25 Mertens K, Bertina RM. Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and extrinsic pathway of blood coagulation. Thromb Haemostas 1982; 47: 96-100
• 26 Østerud B. The intrinsic and extrinsic activation of factor IX. In: Peeters H. (ed.). Protides of the biological fluids. Proceedings of the 28th colloquium. Pergamon Press; Oxford: 233-236 1980
• 27 Marlar RA, Griffin JH. Alternative pathways of thromboplastin-dependent activation of human factor X in plasma. Ann NY Acad Sci 1981; 370: 325-335